aH5N6c / CSL Behring - LARVOL DELTA

Heterologous prime-boost vaccination against H5 avian influenza: Safety and immunogenicity of a MF59-adjuvanted, cell-culture derived H5N6 vaccine. (PubMed, Hum Vaccin Immunother) - "This phase 2 extension study evaluated immunogenicity and safety of MF59-adjuvanted, cell culture-derived H5N6 vaccine (aH5N6c) in adults primed with MF59-adjuvanted, cell culture-derived H5N1 vaccine (aH5N1c) and in unprimed adults...Solicited adverse events were mild or moderate, comparable between groups, and consistent with other MF59-adjuvanted pandemic vaccines; no vaccine-related serious adverse events occurred. Heterologous H5N6 booster vaccination in H5N1-primed adults elicited strong cross-reactive immunity against the priming strain, demonstrating long-lasting immune memory for at least 6 y and supporting heterologous prime-boost strategies for pandemic preparedness against emerging H5 outbreaks."

Clinical • Journal • Preclinical • Infectious Disease • Influenza • Respiratory Diseases

Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/or H5N6 Influenza Vaccine in Adults (clinicaltrials.gov) - P2 | N=480 | Completed | Sponsor: Seqirus | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Influenza • Respiratory Diseases

Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/or H5N6 Influenza Vaccine in Adults (clinicaltrials.gov) - P2 | N=480 | Active, not recruiting | Sponsor: Seqirus | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Influenza • Respiratory Diseases

Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/or H5N6 Influenza Vaccine in Adults (clinicaltrials.gov) - P2 | N=480 | Recruiting | Sponsor: Seqirus | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Influenza • Respiratory Diseases

Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/or H5N6 Influenza Vaccine in Adults (clinicaltrials.gov) - P2 | N=480 | Not yet recruiting | Sponsor: Seqirus

New P2 trial • Infectious Disease • Influenza • Respiratory Diseases

A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine in Adults Primed With H5N1 Influenza Vaccine or Unprimed (clinicaltrials.gov) - P2 | N=260 | Completed | Sponsor: Seqirus | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Influenza • Respiratory Diseases

A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine in Adults Primed With H5N1 Influenza Vaccine or Unprimed (clinicaltrials.gov) - P2 | N=260 | Active, not recruiting | Sponsor: Seqirus | Recruiting ➔ Active, not recruiting | Trial primary completion date: May 2023 ➔ Oct 2022

Enrollment closed • Preclinical • Trial primary completion date • Infectious Disease • Influenza • Respiratory Diseases